CoChat

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy

Open access
Mehdi, Uzma F., Adams-Huet, Beverley, Raskin, Philip, Vega, Gloria L., Toto, Robert D. · 2009 · Journal of the American Society of Nephrology

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Aldosterone promotes glomerular and tubular sclerosis independent of angiotensin II in animal models of diabetic nephropathy. Most human studies testing the renoprotective benefit of adding an angiotensin receptor blocker or a mineralocorticoid receptor antagonist to a regimen based on inhibition of angiotensin-converting enzyme (ACE) used relatively low doses of ACE inhibitors. Furthermore, these studies did not determine whether antiproteinuric effects were independent of BP lowering. We conducted a double-blind, placebo-controlled trial in 81 patients with diabetes, hypertension, and albuminuria (urine albumin-to-creatinine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily). We randomly assigned the patients to placebo, losartan (100 mg daily), or spironolactone (25 mg daily) for 48 wk. We obtained blood and urine albumin, urea, creatinine, electrolytes, A1c, and ambulatory BP at baseline, 24, and 48 wk. Compared with placebo, the urine albumin-to-creatinine ratio decreased by 34.0% (95% CI, -51.0%, -11.2%, P = 0.007) in the group assigned to spironolactone and by 16.8% (95% CI, -37.3%, +10.5%, P = 0.20) in the group assigned to losartan. Clinic and ambulatory BP, creatinine clearance, sodium and protein intake, and glycemic control did not differ between groups. Serum potassium level was significantly higher with the addition of either spironolactone or losartan. In conclusion, the addition of spironolactone, but not losartan, to a regimen including maximal ACE inhibition affords greater renoprotection in diabetic nephropathy despite a similar effect on BP. These results support the need to conduct a long-term, large-scale, renal failure outcomes trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2009070737

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 415

Metadata

Authors
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
  • Mehdi, Uzma F.
  • Adams-Huet, Beverley
  • Raskin, Philip
  • Toto, Robert D.
Venue
Journal of the American Society of Nephrology
Published
2009-12
Volume
20
Issue
12
Pages
2641-2650
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2141386688
Cited by
388
References
46
Citations by year
2026: 8 · 2025: 8 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 27 · 2020: 13 · 2019: 20 · 2018: 12 · 2017: 13 · 2016: 19 · 2015: 32 · 2014: 41 · 2013: 25 · 2012: 42
FWCI
26.27
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Society of Nephrology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (2R01 DK6301001)
  • National Center for Research Resources (M01RR000633, UL1RR024982, M01 RR00633)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
diabetic nephropathy, angiotensin receptor blockers, mineralocorticoid receptor antagonists, ACE inhibitors, lisinopril, losartan, spironolactone, albuminuria, proteinuria, renal protection, serum potassium, hypertension, albumin-creatinine ratio
MeSH terms
Adult, Albuminuria, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Bicarbonates, Blood Pressure, Creatinine, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypertension, Male, Middle Aged, Potassium, Renin-Angiotensin System, Spironolactone, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy. https://app.cochat.ai/papers/10.1681/asn.2009070737
The paper
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009). Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2009070737

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.